Comparing the current results to its competitors, Therapeuticsmd Inc reported Revenue decrease in the 2 quarter 2026 year on year by -8.72 %, despite the revenue increase by the most of its competitors of 12.7 %, recorded in the same quarter.
Therapeuticsmd Inc Net Income in the 2 quarter 2026 fell year on year by -71.87%, while most of its competitors have experienced a contraction in net income by -6.1 %.
May 13, 2024
TherapeuticsMD, Inc., a company that notably owns the rights to pharmaceutical royalties (NASDAQ: TXMD), has recently announced their first quarter financial results for the fiscal year 2024. As a respected journal in the field of scientific inquiry and pharmaceutical advancements, we deem it crucial to conduct an extensive review of this eminently influential industry player, juxtaposing its financial performance with its rivals.According to the financial results released, the financial disposition of TherapeuticsMD in the first quarter ended March 31, 2024, was characterized by a net loss from continuing operations, set at $(0.8) million, or $(0.07) per basic and diluted common share. In comparison to the ...
May 12, 2024
TherapeuticsMD Reports First Quarter 2024 Financial Results with Net Loss from Continuing OperationsTherapeuticsMD, Inc. (TherapeuticsMD or the Company) (NASDAQ: TXMD) recently released its financial results for the first quarter ending March 31, 2024. The company reported a net loss from continuing operations of $0.8 million, or $0.07 per basic and diluted common share, compared to a net loss of $2.3 million, or $0.XX per share, for the same period in the previous year.Despite the reported net loss, TherapeuticsMD has faced tough competition from its peers. Comparing the current results to its competitors, the company experienced a 0% decrease in revenue in the third quarter of 2023, while its competitors r...
May 10, 2024
As the first quarter of 2024 concludes, TherapeuticsMD, Inc. (NASDAQ: TXMD), a healthcare-focused company specialising in securing royalties for pharmaceutical products, has made considerable strides towards achieving its financial goals. However, an insightful look into the specifics reveals a mix of wins and losses, suggesting that the journey ahead may still have a few hurdles.In the first quarter ended March 31, 2024, TherapeuticsMD reported a net loss from continuing operations of $(0.8) million, equivalent to $(0.07) per basic and diluted share. This constitutes an improvement when compared to the comparative quarter of previous year where the net loss was $(2.3) million, implying a reduction in losses...
Esperion Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for addressing cardiovascular diseases.
Veru Inc operates as a pharmaceutical company primarily focused on developing and commercializing medicines for men's and women's health. With a combination of in-house research and partnerships, Veru Inc aims to address unmet medical needs by providing innovative therapies and products. Their business model encompasses both the development of new pharmaceuticals and the marketing and distribution of their existing products in the healthcare market.
Immunoprecise Antibodies Ltd operates as a contract research organization specializing in the discovery and development of therapeutic antibodies to advance the treatment of various diseases. Through customized antibody solutions and a comprehensive portfolio of services, they offer support to pharmaceutical and biotechnology companies to accelerate their drug development processes.
Biomarin Pharmaceutical Inc operates as a biotechnology company, specializing in the development and commercialization of innovative therapies for rare genetic diseases. Their business model revolves around conducting extensive research and development to identify and address unmet medical needs, manufacturing and marketing their approved products, and collaborating with strategic partners to maximize the reach and impact of their therapies worldwide. By focusing on rare diseases, Biomarin leverages their expertise to provide targeted and innovative treatments, ultimately improving the lives of patients in need.
Opko Health Inc is a biotechnology and pharmaceutical company that operates through various business segments. The company primarily focuses on diagnostics, developing and commercializing novel diagnostic tests for various conditions. Additionally, Opko Health engages in the production and sale of pharmaceuticals and vaccines, as well as the research and development of new medical technologies.
Sources:
Therapeuticsmd Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Therapeuticsmd Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
